MiniMed Expands Sensor Portfolio with Abbott's Dual Glucose-Ketone Sensors
Event summary
- MiniMed and Abbott have expanded their partnership to commercialize dual glucose-ketone sensors for integration with MiniMed's smart dosing systems.
- The sensors aim to enable early detection of rising ketones to prevent diabetic ketoacidosis (DKA), a life-threatening complication.
- Abbott's dual glucose-ketone systems have received CE Mark but are not yet cleared or available for sale in the United States.
- The sensors will be the same size as Abbott's Instinct sensor, the world's smallest and thinnest sensor.
The big picture
This partnership underscores the growing trend of integrating advanced sensor technology into diabetes management systems to improve patient outcomes. By adding ketone monitoring to its existing glucose monitoring capabilities, MiniMed aims to reduce the risk of DKA, a significant cause of hospitalization and mortality in diabetes patients. The collaboration with Abbott leverages existing sensor technology to enhance MiniMed's smart dosing systems, potentially setting a new standard in automated insulin delivery.
What we're watching
- Regulatory Approval
- The pace at which Abbott's dual glucose-ketone systems gain FDA clearance will determine the timeline for commercialization.
- Market Adoption
- Whether MiniMed can effectively integrate and market the new sensors to its existing user base and attract new customers.
- Competitive Dynamics
- How this partnership positions MiniMed against competitors in the diabetes technology space.
Related topics